Presence of Particulate Matter Leads to Hospira Injection Recall

Presence of Particulate Matter Leads to Hospira Injection Recall
Image: NCCC
April 14, 2016

Hospira has announced a recall for a medication due to doubts over its safety.

The pharmaceutical company is recalling one lot of 50 percent Magnesium Sulfate Injection, USP, 10 g/20 mL Single-dose vials. The firm has received a confirmed customer complaint of the presence of particulate matter, within one single-dose fliptop vial.

The affected product bears lot number 50-343-DK, expiration date 02/01/2017, and National Drug Code (NDC) 0409-2168-02. It was packed in a 25 count box, and was distributed nationwide from March 2015 through June 2015.

If the particulate is detected prior to administration, patient harm is unlikely. However, if not observed, it may result in localized swelling, redness, pain at the site of administration or veins, allergic reactions to the foreign particle, microembolic effects as well as possible fetal harm.

To date, Hospira has not received reports of any adverse events associated with this issue for this lot.

Anyone with an existing inventory of the recalled lot should stop use and distribution and quarantine the product immediately. Inform health care professionals in your organization of this recall.

Customers with questions about this recall can contact Hospira at (800) 441-4100.